La Trobe
EXOSOM~1.PDF (293.28 kB)

Exosomes Derived from Human Primary and Metastatic Colorectal Cancer Cells Contribute to Functional Heterogeneity of Activated Fibroblasts by Reprogramming Their Proteome

Download (293.28 kB)
journal contribution
posted on 12.08.2021, 06:32 by Alin Rai, David GreeningDavid Greening, Maoshan Chen, Rong Xu, Hong Ji, Richard SimpsonRichard Simpson
Cancer-associated fibroblasts (CAFs) are a heterogeneous population of activated fibroblasts that constitute a dominant cellular component of the tumor microenvironment (TME) performing distinct functions. Here, the role of tumor-derived exosomes (Exos) in activating quiescent fibroblasts into distinct functional subtypes is investigated. Proteomic profiling and functional dissection reveal that early- (SW480) and late-stage (SW620) colorectal cancer (CRC) cell-derived Exos both activated normal quiescent fibroblasts (α-SMA − , CAV + , FAP + , VIM + ) into CAF-like fibroblasts (α-SMA + , CAV − , FAP + , VIM + ). Fibroblasts activated by early-stage cancer-exosomes (SW480-Exos) are highly pro-proliferative and pro-angiogenic and display elevated expression of pro-angiogenic (IL8, RAB10, NDRG1) and pro-proliferative (SA1008, FFPS) proteins. In contrast, fibroblasts activated by late-stage cancer-exosomes (SW620-Exos) display a striking ability to invade through extracellular matrix through upregulation of pro-invasive regulators of membrane protrusion (PDLIM1, MYO1B) and matrix-remodeling proteins (MMP11, EMMPRIN, ADAM10). Conserved features of Exos-mediated fibroblast activation include enhanced ECM secretion (COL1A1, Tenascin-C/X), oncogenic transformation, and metabolic reprogramming (downregulation of CAV-1, upregulation of glycogen metabolism (GAA), amino acid biosynthesis (SHMT2, IDH2) and membrane transporters of glucose (GLUT1), lactate (MCT4), and amino acids (SLC1A5/3A5)). This study highlights the role of primary and metastatic CRC tumor-derived Exos in generating phenotypically and functionally distinct subsets of CAFs that may facilitate tumor progression.

Funding

This work was supported by NHMRC Project grants #1057741 and #1139489 (D.W.G.). D.W.G. was supported by La Trobe Institute for Molecular Science Fellowship and La Trobe University Leadership RFA grant. M.C., R.X., W.S., D.W.G. and R.J.S. acknowledge funding support from La Trobe University, Melbourne, Australia.

History

Publication Date

01/01/2019

Journal

Proteomics

Volume

19

Issue

8

Article Number

1800148

Pagination

20p.

Publisher

Wiley-Blackwell

ISSN

1615-9853

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.